Sarissa Capital Management LP — 13F Holdings & Portfolio

CIK 1577524 · latest 13F-HR filed 2026-08-14

Sarissa Capital Management LP manages $177.9M in 13F-reported U.S. long-equity assets across 10 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are INVA (24.14%), IRWD (21.75%), AMRN (15.00%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 0, added to 6, and trimmed 2.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
500 WEST PUTNAM AVENUE, SUITE 400
GREENWICH, CT 06830
Phone
(203) 302-2330
Filing Manager
Sarissa Capital Management LP
GREENWICH, CT
Signatory
Alexander J. Denner, Ph.D.
Chief Investment Officer
Loading holdings…
AUM

$177.9M

Long-equity book

Holdings

10

Distinct positions

Period

2026-06-30

Filed 2026-08-14

Q/Q Activity

+1 / −0 / ↑6 / ↓2

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • IRONWOOD PHARMACEUTICALS INC$6.4M +19.9%
  • LANTHEUS HLDGS INC$5.9M +46.3%
  • CYTOKINETICS INC$4.4M +29.3%
  • NEUROCRINE BIOSCIENCES INC$4.3M +27.9%
  • BIOHAVEN LTD$3.9M +81.9%
Show all 6

Top Trims

  • INNOVIVA INC-$6.7M -13.5%
  • REGENERON PHARMACEUTICALS-$624.7K -19.3%
Show all 2

New Positions

  • BIOGEN INC$205.3K
Show all 1

Exited Positions

  • No exits this quarter.
Show all 0
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 INNOVIVA INC INVA 45781M101 $42.9M 24.14% 1,890,604 SH
2 IRONWOOD PHARMACEUTICALS INC IRWD 46333X108 $38.7M 21.75% 9,188,635 SH
3 AMARIN CORP PLC AMRN 023111404 $26.7M 15.00% 1,673,395 SH
4 NEUROCRINE BIOSCIENCES INC NBIX 64125C109 $19.6M 11.04% 116,533 SH
5 CYTOKINETICS INC CYTK 23282W605 $19.5M 10.95% 228,623 SH
6 LANTHEUS HLDGS INC LNTH 516544103 $18.5M 10.41% 166,919 SH
7 BIOHAVEN LTD BHVN G1110E107 $8.7M 4.87% 582,312 SH
8 REGENERON PHARMACEUTICALS REGN 75886F107 $2.6M 1.47% 4,190 SH
9 VOR BIOPHARMA INC VOR 929033207 $467.6K 0.26% 25,399 SH
10 BIOGEN INC BIIB 09062X103 $205.3K 0.12% 950 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $177.9M 10 0000899140-26-000879
2026-03-31 2026-05-15 $157.6M 9 0000899140-26-000574
2025-12-31 2026-02-17 $222.9M 9 0000899140-26-000256
2025-09-30 2025-11-14 $180.4M 8 0000899140-25-001320